HUNTSVILLE, AL – CFD Research Corporation (CFD) announced the formation of Kalm Therapeutics (Kalm Tx) this week to bring a much-needed non-steroidal eczema treatment to patients with mild to moderate atopic dermatitis. The condition affects more than 16 million people in the United States.

“After several years of research and development, it is rewarding to see our innovations reach the market and make a difference in the lives of eczema patients through the formation of Kalm Therapeutics,” said Sameer Singhal, CFD’s president and CEO.

Kalm Tx was launched as an independent entity, stemming from the innovative research and development efforts of CFD Research. Kalm’s new product, a controlled-release eczema wrap (CREW) utilizes a proprietary continuous dose technology to deliver an easier-to-use and natural eczema treatment to patients. CREW delivers its eczema-relieving compound over 24 hours, an improvement on topical steroids requiring 3-5 daily applications.

In conjunction with the company formation, Chris Seibert was named CEO of the new venture. Seibert, who lives in Athens, has previous experience at public companies Stereotaxis of St. Louis, Mo., and Titan Medical of Chapel Hill, N.C.

At Titan Medical, he led the clinical and business development efforts to develop a single-port robotic platform that eventually licensed its intellectual property to Medtronic, Intuitive Surgical, and Johnson and Johnson, all market leaders in the laparoscopic, a kind of exploratory surgery using a laparoscope, and robotic surgical fields.

“Kalm Therapeutics is focused on developing single-use patches to naturally treat eczema and eventually other common skin conditions,” Seibert said. “Our patent-pending Controlled Release Eczema Wrap addresses a vital gap in the treatment paradigm of this life-altering disease that affects over 10% of the global population. I am excited to be leading this new venture as we bring a natural alternative to the market.”

For more information, please visit www.cfd-research.com.